This is a summary of the European public assessment report (EPAR) for Opatanol. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Opatanol.
Therapeutic Indication
Treatment of ocular signs and symptoms of seasonal allergic conjunctivitis.
Therapeutic Area (MeSH)
ATC Code
S01GX09
ATC Item
N/A
Pharmacotherapeutic Group
Ophthalmologicals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| olopatadine hydrochloride | N/A | olopatadine hydrochloride |
EMA Name
Opatanol
Medicine Name
Opatanol
Aliases
N/ANo risk management plan link.
